What does this state matrix cover?

For each state it lists the regulatory bodies, the non-resident permit a 503B outsourcing facility needs to ship in, the telehealth statute or rule that governs prescribing, the visit standard for a first peptide or GLP-1 prescription, interstate compact status where stated, and a short enforcement note.

Where does the data come from?

Each row summarizes public statutes, board rules, and board advisories that are cited on the matching state compliance page. The matrix is a condensed view of those notes, not additional research, and it is not legal advice.

Why are only some states listed?

Only states with a fully cited compliance page are included in the matrix. States are added as their pages are reviewed, and the review date is shown on this page.

Can I download or reuse the table?

Yes. The CSV export is free to download and cite with attribution to Direct Peptide Sales and a link to this page.

Does Direct Peptide Sales sell peptides in these states?

No. We do not sell, ship, or hold product. We verify licensed practices and introduce them to telehealth prescribers and 503A or 503B pharmacy sources that hold the right permits for their states.

What does this state matrix cover?

For each state it lists the regulatory bodies, the non-resident permit a 503B outsourcing facility needs to ship in, the telehealth statute or rule that governs prescribing, the visit standard for a first peptide or GLP-1 prescription, interstate compact status where stated, and a short enforcement note.

Where does the data come from?

Each row summarizes public statutes, board rules, and board advisories that are cited on the matching state compliance page. The matrix is a condensed view of those notes, not additional research, and it is not legal advice.

Why are only some states listed?

Only states with a fully cited compliance page are included in the matrix. States are added as their pages are reviewed, and the review date is shown on this page.

Can I download or reuse the table?

Yes. The CSV export is free to download and cite with attribution to Direct Peptide Sales and a link to this page.

Does Direct Peptide Sales sell peptides in these states?

No. We do not sell, ship, or hold product. We verify licensed practices and introduce them to telehealth prescribers and 503A or 503B pharmacy sources that hold the right permits for their states.

What exactly does Direct Peptide Sales do?

We are a referral and introduction service. We verify your business and the states it serves, then introduce you to licensed telehealth prescribers and 503A or 503B pharmacies. You contract directly with them. We do not sell, price, prescribe, compound, bill, or ship any product.

How fast can my practice be introduced to a source?

Timing depends on your business details, states served, and partner fit. DPS does not guarantee an introduction or launch date. The independent partners determine their own onboarding requirements.

Nothing to apply, and we do not charge practices a fee. Product pricing, account terms, and any minimums are set by the pharmacy or prescriber you contract with, not by us.

Where do the peptides come from and are they verified?

Ask the independent pharmacy to confirm current product status, applicable licenses, and preparation-specific quality documentation. DPS does not test or certify products. The COA library contains illustrative examples, not proof for a future lot.

Who handles prescribing, billing, and shipping?

The licensed prescriber and the pharmacy do. Prescribing is the provider's independent clinical decision, and dispensing, billing, and shipping sit with the pharmacy. We are not part of that transaction.

What if I'm not a licensed clinic?

Non-licensed wellness businesses such as coaches, gyms, studios, and nutrition practices can be introduced to a licensed telehealth prescriber who owns the clinical relationship. You never prescribe, hold, or dispense product.

How do you vet the sources you introduce?

Before contracting, independently verify the source legal identity, licenses for the relevant states, preparation-specific documentation, and written responsibilities. A facility license or COA does not establish that every proposed product may lawfully be prescribed or supplied.

Which states do you serve?

Coverage depends on the states your business serves and the independent partners' licenses. An introduction is not authorization to prescribe or ship into a state.

Reference data

Peptide and GLP-1 regulations by state

Name: Peptide and GLP-1 Regulations by State (2026 Matrix)
Creator: Direct Peptide Sales
License: https://creativecommons.org/licenses/by/4.0/

A single table that answers the questions clinics ask before launching in a new state: who regulates it, what permit the pharmacy needs, which telehealth rule applies, and what the first visit has to look like. Each row links to a fuller state page with primary citations.

Direct Peptide Sales is a referral service for licensed practices and wellness businesses. We introduce you to licensed prescribers and 503A/503B pharmacies. We do not sell, prescribe, bill, or ship product.

Last reviewed September 2, 2026 · Editorial policy

How to read the matrix

Columns are chosen to match the diligence checklist most practices run.

Regulatory bodies: the pharmacy and medical boards that hear complaints and set rules
503B non-resident requirement: the permit an out-of-state outsourcing facility needs before shipping office-use stock in
Telehealth authority: the statute or board rule that governs a remote prescriber-patient relationship
First-prescription visit standard: whether a video visit is expected before the first peptide or GLP-1 prescription
Interstate compact: whether the state accepts the Interstate Medical Licensure Compact, where the source states it

Patterns worth noticing

Three things repeat across the table. Nearly every state expects a synchronous video visit before a first prescription, with asynchronous refills allowed under a documented care plan. Every state requires the shipping pharmacy to hold its own non-resident permit, so the pharmacy's license list matters as much as the prescriber's. And the states with the most program growth, Florida and Texas, are also the ones with the most active board advisories on compounded GLP-1 marketing.

Frequently asked questions

What does this state matrix cover?: For each state it lists the regulatory bodies, the non-resident permit a 503B outsourcing facility needs to ship in, the telehealth statute or rule that governs prescribing, the visit standard for a first peptide or GLP-1 prescription, interstate compact status where stated, and a short enforcement note.
Where does the data come from?: Each row summarizes public statutes, board rules, and board advisories that are cited on the matching state compliance page. The matrix is a condensed view of those notes, not additional research, and it is not legal advice.
Why are only some states listed?: Only states with a fully cited compliance page are included in the matrix. States are added as their pages are reviewed, and the review date is shown on this page.
Can I download or reuse the table?: Yes. The CSV export is free to download and cite with attribution to Direct Peptide Sales and a link to this page.
Does Direct Peptide Sales sell peptides in these states?: No. We do not sell, ship, or hold product. We verify licensed practices and introduce them to telehealth prescribers and 503A or 503B pharmacy sources that hold the right permits for their states.
What exactly does Direct Peptide Sales do?: We are a referral and introduction service. We verify your business and the states it serves, then introduce you to licensed telehealth prescribers and 503A or 503B pharmacies. You contract directly with them. We do not sell, price, prescribe, compound, bill, or ship any product.
How fast can my practice be introduced to a source?: Timing depends on your business details, states served, and partner fit. DPS does not guarantee an introduction or launch date. The independent partners determine their own onboarding requirements.
What does it cost?: Nothing to apply, and we do not charge practices a fee. Product pricing, account terms, and any minimums are set by the pharmacy or prescriber you contract with, not by us.
Where do the peptides come from and are they verified?: Ask the independent pharmacy to confirm current product status, applicable licenses, and preparation-specific quality documentation. DPS does not test or certify products. The COA library contains illustrative examples, not proof for a future lot.
Who handles prescribing, billing, and shipping?: The licensed prescriber and the pharmacy do. Prescribing is the provider's independent clinical decision, and dispensing, billing, and shipping sit with the pharmacy. We are not part of that transaction.
What if I'm not a licensed clinic?: Non-licensed wellness businesses such as coaches, gyms, studios, and nutrition practices can be introduced to a licensed telehealth prescriber who owns the clinical relationship. You never prescribe, hold, or dispense product.
How do you vet the sources you introduce?: Before contracting, independently verify the source legal identity, licenses for the relevant states, preparation-specific documentation, and written responsibilities. A facility license or COA does not establish that every proposed product may lawfully be prescribed or supplied.
Which states do you serve?: Coverage depends on the states your business serves and the independent partners' licenses. An introduction is not authorization to prescribe or ship into a state.

State rules matrix

Download CSV

9 states. Reviewed 2026-09-02. Public-record summaries, not legal advice.

Peptide and GLP-1 Regulations by State (2026 Matrix)
State	Regulatory bodies	503B non-resident requirement	Telehealth authority	First-prescription visit standard	Interstate compact	Enforcement note
Arizona	Board of Pharmacy; Medical Board; Naturopathic Physicians Medical Board	AZ Non-Resident Pharmacy Permit	ARS 36-3606	Audio-video visit; async accepted for refills with care plan	IMLC accepted	Permissive for med spa programs; naturopaths hold prescriptive authority under ARS 32-1502
Colorado	State Board of Pharmacy; Colorado Medical Board	CO Non-Resident Prescription Drug Outlet Registration	CRS 12-240-107	Video or asynchronous under a documented plan	IMLC accepted	Standard enforcement, attentive to sterile compounding practice
Florida	Board of Pharmacy; Board of Medicine (DOH)	FL Non-Resident Sterile Compounding Permit	FL Statute 456.47 (telehealth registration)	Synchronous visit; async-only generally insufficient	Telehealth registration route	High scrutiny of marketing claims and cash-pay structures; BOP advisories on compounded semaglutide sourcing
Georgia	Board of Pharmacy; Composite Medical Board	GA non-resident pharmacy licensure	GCMB Rule 360-3-.07	Video visit; audio-only typically insufficient	Not stated	Increased board activity on cash-pay marketing through 2025
Illinois	IDFPR (Pharmacy and Medical)	IDFPR 503B non-resident registration	Illinois Telehealth Act (225 ILCS 150)	Video standard; audio-only permitted narrowly	Not stated	Regular IDFPR review of GLP-1 compounding marketing and dispensing chain
Nevada	State Board of Pharmacy; Board of Medical Examiners	NV non-resident permit (NRS 639); COA on request	NRS 629.515	Video visit; async accepted for refills with plan of care	IMLC accepted	Active BOP enforcement on marketing and chain of custody
New York	NYSED Office of the Professions; DOH Bureau of Pharmacy; BNE	NY Non-Resident Establishment registration	Public Health Law 2999-cc	Established relationship; async-only risky for first Rx	IMLC not accepted	State-level USP 797 equivalent plus extra sterile compounding recordkeeping
Tennessee	Board of Pharmacy; Board of Medical Examiners	TN non-resident permit	TCA 63-6-209	Video visit for first Rx; async refills with care plan	Interstate compact license accepted	Board guidance on GLP-1 compounding oversight issued 2024-2025
Texas	State Board of Pharmacy; Texas Medical Board	TX Non-Resident Class E Pharmacy license	Occupations Code Ch. 111; TMB Rule 174	Video visit; audio-only alone typically insufficient	Not stated	TMB advisories on GLP-1 compounding and marketing; frequent TSBP audits

Cite as: Direct Peptide Sales, "Peptide and GLP-1 Regulations by State (2026 Matrix)", https://directpeptidesales.com/peptide-regulations-by-state. Licensed CC BY 4.0.

Get introduced to sources licensed for your states

Tell us the states your patients live in and we will introduce prescribers and 503A/503B pharmacies that already hold the right permits.

Get Started →